59 filings
Page 2 of 3
8-K
pcfnmg7s 1r
2 Dec 22
Amendments to Articles of Incorporation or Bylaws
4:14pm
8-K
z6zuth qcz3wenp0
10 Nov 22
Passage Bio Reports Third Quarter 2022 Financial Results And Provides Business Updates
7:03am
8-K
vfglzafn2lf6nvqh49
11 Oct 22
Departure of Directors or Certain Officers
7:15am
8-K
zhuxmjnoxja6se8qwro
11 Aug 22
Other Events
7:10am
8-K
l9rgk6vl6ij
4 Aug 22
Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights
7:20am
8-K
168oiih4zz90yk
6 Jul 22
Departure of Directors or Certain Officers
7:00am
8-K
ze6np eik52x
8 Jun 22
Other Events
7:44am
8-K
2bfzviyv bsoi
1 Jun 22
Departure of Directors or Certain Officers
8:00am
8-K
lj4 brvidav0fzbb
18 May 22
Passage Bio Presents New Interim Clinical and Biomarker
7:16am
8-K
olrqyfuw atq
16 May 22
Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights
7:15am
8-K
adis4cr 1loex4
15 Mar 22
Other Events
7:10am
8-K
gwely2rh
11 Mar 22
Departure of Directors or Certain Officers
5:00pm
8-K
0tjb8
10 Mar 22
Other Events
7:13am
8-K
rs1lkljik8091s4lp
3 Mar 22
Passage Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
7:15am
8-K
445dh
11 Feb 22
Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium
11:00am
8-K
azt6b5 0vn2e6
10 Jan 22
Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline
8:00am
8-K
nmyzlf7d74l dfkljmq
17 Dec 21
Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis
7:01am
8-K
2vprhy4pe2fhdb0ju
4 Nov 21
Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights
8:00am
8-K
t08 d98b9n90squk
1 Nov 21
Departure of Directors or Certain Officers
5:01pm
8-K
3khbfsuu42 ev
4 Oct 21
Regulation FD Disclosure
7:31am